AI-powered therapeutic target discovery

FW Pun, IV Ozerov, A Zhavoronkov - Trends in pharmacological sciences, 2023‏ - cell.com
Disease modeling and target identification are the most crucial initial steps in drug
discovery, and influence the probability of success at every step of drug development …

Artificial intelligence for drug discovery: are we there yet?

C Hasselgren, TI Oprea - Annual Review of Pharmacology and …, 2024‏ - annualreviews.org
Drug discovery is adapting to novel technologies such as data science, informatics, and
artificial intelligence (AI) to accelerate effective treatment development while reducing costs …

A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models

F Ren, A Aliper, J Chen, H Zhao, S Rao, C Kuppe… - Nature …, 2024‏ - nature.com
Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung disease with a high
mortality rate. Putative drug targets in IPF have failed to translate into effective therapies at …

AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor

F Ren, X Ding, M Zheng, M Korzinkin, X Cai, W Zhu… - Chemical …, 2023‏ - pubs.rsc.org
The application of artificial intelligence (AI) has been considered a revolutionary change in
drug discovery and development. In 2020, the AlphaFold computer program predicted …

PandaOmics: an AI-driven platform for therapeutic target and biomarker discovery

P Kamya, IV Ozerov, FW Pun, K Tretina… - Journal of chemical …, 2024‏ - ACS Publications
PandaOmics is a cloud-based software platform that applies artificial intelligence and
bioinformatics techniques to multimodal omics and biomedical text data for therapeutic …

From understanding diseases to drug design: can artificial intelligence bridge the gap?

AC Pushkaran, AA Arabi - Artificial Intelligence Review, 2024‏ - Springer
Artificial intelligence (AI) has emerged as a transformative technology with significant
potential to revolutionize disease understanding and drug design in healthcare. AI serves as …

Revolutionizing drug discovery: A comprehensive review of AI applications

R Dhudum, A Ganeshpurkar, A Pawar - Drugs and Drug Candidates, 2024‏ - mdpi.com
The drug discovery and development process is very lengthy, highly expensive, and
extremely complex in nature. Considering the time and cost constraints associated with …

Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor

Y Fu, X Ding, M Zhang, C Feng, Z Yan, F Wang… - Nature …, 2024‏ - nature.com
Hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors have been approved for
treating renal anemia yet have failed clinical testing for inflammatory bowel disease because …

Integrating artificial intelligence into the modernization of traditional Chinese medicine industry: a review

E Zhou, Q Shen, Y Hou - Frontiers in pharmacology, 2024‏ - frontiersin.org
Traditional Chinese medicine (TCM) is the practical experience and summary of the
Chinese nation for thousands of years. It shows great potential in treating various chronic …

A comprehensive AI‐driven analysis of large‐scale omic datasets reveals novel dual‐purpose targets for the treatment of cancer and aging

FW Pun, GHD Leung, HW Leung, J Rice… - Aging …, 2023‏ - Wiley Online Library
As aging and tumorigenesis are tightly interconnected biological processes, targeting their
common underlying driving pathways may induce dual‐purpose anti‐aging and anti‐cancer …